Floatz logo

Cysteine

Erythropoietic Protoporphyria

FDA Office of Orphan Products DevelopmentSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Erythropoietic Protoporphyria cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Cysteine is also rated in:

vitamin D deficiencyDormant
CC
Indicative ·
43 / 100
View asset →
glioblastomaDormant
D
Indicative ·
30 / 100
View asset →
gliomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →